A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 304-309

  Vazquez, José A ^a,e   Schranz, Jennifer A ^b   Clark, Kay ^b   Goldstein, Beth P ^b   Reboli, Annette ^c   Fichtenbaum, Carl ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vicuron Pharmaceuticals   (United States)

^c Department of Anesthesiology   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

Anidulafungin; Azole refractory candidiasis; Mucosal candidiasis

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOSCOPY; ESOPHAGUS CANDIDIASIS; FEMALE; FLUSHING; FOLLOW UP; HUMAN; HYPOKALEMIA; MACULOPAPULAR RASH; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OROPHARYNX CANDIDIASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; AIDS RELATED COMPLEX; ANTIFUNGAL RESISTANCE; CANDIDIASIS; ESOPHAGUS DISEASE; MIDDLE AGED; MUCOSA; THRUSH;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTIFUNGAL; AZOLES; CANDIDIASIS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; ESOPHAGEAL DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE;

EID: 47049108146     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817af47a     Document Type: Article

References (31)

1. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11:382-402.
2. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. 2000;30:749-756.
3. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy. 1999;19:76-87.
4. Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr. 2002;31:183-187.
5. Masia Canuto M, Gutierrez Rodero F, Ortiz de la Tabla Ducasse V. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2000;19:593-601.
6. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-225.
7. Revankar SG, Kirkpatrick WR, McAtee RK, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;174: 821-827.
8. Sobel JD, Ohmit SE, Schuman P, et al. HIV Epidemiology Research Study (HERS) Group. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2001;183:286-293.
9. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother. 2000;44:747-751.
10. Fichtenbaum CJ, Zackin R, Rajicic N, et al. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS. 2000;14:845-852.
11. Kartsonis NA, Saah A, Lipka CJ, et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother. 2004; 53:878-881.
12. Cancidas (caspofungin) 70 mg summary of product characteristics [Caspofungin package insert]. Haarlem, The Netherlands: Merck, Sharp, & Dohme Ltd; 2003.
13. Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis. 2001;33:1069-1075.
14. White TC, Holleman S, Dy F, et al. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002;46:1704-1713.
15. Muller FM, Weig M, Peter J, et al. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidiasis. J Antimicrob Chemother. 2000;46:338-340.
16. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994;48:471-497.
17. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect. 2001; 7:11-16.
18. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47:3149-3154.
19. Messer SA, Kirby JT, Sader HS, et al. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother. 2004;54:1051-1056.
20. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-2024.
21. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-775.
22. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590-598.
23. Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Clin Microbiol Infect. 2003;9(Suppl 1):290-291.
24. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. 2nd ed. Wayne, PA: NCCLS; 2002. NCCLS Document M27-A2.
25. Laine L. The natural history of esophageal candidiasis after successful treatment in patients with AIDS. Gastroenterology. 1994;107:744-746.
26. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials. 2000; 1:47-59.
27. Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998;26:556-565.
28. Phillips P, Zemcov J, Mahmood W, et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal long-term continuous versus intermittent fluconazole therapy. AIDS. 1996;10:1369-1376.
29. Moudgal V, Little T, Boikov D, et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49: 767-769.
30. Ali A, Vasquez G, Vager D, Vazquez JA. Pharmacodynamics of echinocandins against Candida species, including strains with decreased susceptibility to micafungin while retaining anidulafungin susceptibility. In: Program and Abstracts Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16-20 September 2007. American Society for Microbiology; Washington, D.C.
31. Hernandez S, Lopez-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004;48:1382-1383.